Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T10707 |
CCK-B Receptor Antagonist 2
|
Others | Others |
CCK-B Receptor Antagonist 2 is a potent and orally active antagonist of Gastrin/CCK-B (IC50: 0.43 nM). It also inhibits gastrin/CCK-A activity (IC50: 1.82 μM). | |||
T13261 |
CCK-B Receptor Antagonist 1
|
Others | Others |
CCK-B Receptor Antagonist 1 is a cholecystokinin B (CCK-B) receptor agonist and has the potential of reducing the secretion of gastric acid. | |||
TP1197 |
Sincalide
SQ19844,辛卡利特,CCK-8,Cholecystokinin octapeptide |
Others | Others |
Sincalide (CCK-8) 是一种速效的胆囊收缩素的氨基酸多肽激素类似物,可在胆囊造影术中静脉使用。它的肝胆生理作用是增加胆汁的分泌,使胆囊收缩并使 Oddi 的括约肌松弛,从而使胆汁排入十二指肠。它是一种通过注射促进胆囊收缩并帮助诊断胆囊和胰腺疾病的药物。 | |||
T1052 |
Proglumide
二丙谷酰胺 |
cholecystokinin | GPCR/G Protein |
Proglumide (Binoside) 是一种非肽的、口服具有活性的胆囊收缩素(CCK)-A/B 受体拮抗剂。它能够选择性阻断 CCK 在中枢神经系统中的作用。它能够抑制胃分泌,具有保护胃十二指肠粘膜的能力,并表现出抗癫痫和抗氧化活性。 | |||
T16906 |
Sograzepide
YM-220,Netazepide,YF 476 |
Others | Others |
Sograzepide is an effective and highly selective Gastrin/CCK-B antagonist (IC50: 0.1 nM), has an inhibitory effect on Gastrin/CCK-A activity (IC50: 502 nM). Sograzepide replaces the specific binding of [125I]CCK-8 to the rat brain, cloned canine, and cloned human Gastrin/CCK-B receptors (Ki: 0.068, 0.62 and 0.19 nM, respectively). | |||
T22666 |
CI-988
CI 988 |
Others | Others |
CCK2 (CCK-B) receptor antagonist | |||
T25139 |
BC 197
Boc-asp-tyr(SO3H)-ahx-lys-trp-ahx-asp-phe-NH2,BC197,BC-197 |
||
BC 197 is a selective CCK-B agonist. | |||
T27014 |
CI-1015
CI1015,CI 1015,PD 144598 |
||
CI-1015 is a CCK-B receptor antagonist with oral activity. | |||
T26197 |
Snf 8815
Snf8815,Snf-8815,28-Mephe-31-N-meile-cck (26-33) |
||
Snf 8815 is an antagonist of cholecystokinin-B (CCK-B). | |||
T23946 |
DA-3934
UNII-J353803KRG |
||
DA-3934 has a high affinity for gastrin/CCK-B receptors and high selectivity over CCK-A receptors. DA-3934 and its methyl ester derivative inhibited pentagastrin-induced gastric acid secretion in rats in a dose-dependent manner. | |||
T28331 |
PD 136450
Cam1189,PD136450,Cam-1189,PD-136450,Cam 1189 |
||
Cholecystokinin type B receptor antagonist PD-136,450 is a partial secretory agonist in the stomach and a full agonist in the pancreas of the rat. Gastrin (cholecystokinin type B (CCK-B)) receptor antagonists may help to elucidate the physiological role o | |||
T27774 |
L-740093
L 740093 |
||
L-740093 is a specific antagonist of CCK-B receptor. | |||
T17274 |
YM022
|
CCR | Immunology/Inflammation; Microbiology/Virology |
YM022 is a highly effective and selective gastrin/cholecystokinin (CCK)-B receptor antagonist. YM022 can inhibit gastrin-induced gastric acid secretion and histidine decarboxylase activation in vivo. YM022 shows the Ki values of 68 pM and 63 nM for CCK-B and CCK-A receptor, respectively. | |||
T26482 |
A-57696
|
||
A-57696 is a cholecystokinin antagonist with selective for cortical CCK-B receptors (IC50 = 25 nM). | |||
T62039 | L-365260 hemihydrate | ||
L-365260 hemihydrate 是选择性的、具有口服活性的非肽胃泌素和脑胆囊收缩素受体 (CCK-B) 拮抗剂,Kis 值分别为 1.9 nM 和 2.0 nM。L-365260 hemihydrate 以竞争性方式与豚鼠胃泌素和脑 CCK 受体相互作用。 | |||
T12544 | Proglumide hemicalcium | Others | Others |
Proglumide hemicalcium is a antagonist of nonpeptide and orally active cholecystokinin (CCK)-A/B receptors, has antiepileptic and antioxidant activities. | |||
T27772 |
L-736380
L-736,380,L 736380,L736,380,L 736,380 |
||
L-736380 is a CCK-B receptor antagonist. L-736,380 dose-dependently inhibited gastric acid secretion in anesthetized rats (ID(50), 0.064 mg/kg) and ex vivo binding of [(125)I]CCK-8S in BKTO mice brain membranes (ED(50), 1.7 mg/kg). | |||
T8761 |
[Leu15]-Gastrin I human
Amino Acid Sequence Glp-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Leu-Asp-Phe-NH2 |
Others | Others |
[Leu15]-Gastrin I human (Amino Acid Sequence Glp-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Leu-Asp-Phe-NH2) 基因编码人体内的蛋白质 [Leu15]-胃泌素 I。在人类染色体中,GAST 基因定位于 17q21.2。胃窦中的 G 细胞产生 [Leu15]-胃泌素 I 的前体前胃泌素。前胃泌素经过裂解和加工产生胃泌素,它对整个胃肠道上皮细胞具有营养作用。胃泌素对消化系统的生长至关重要,并刺激壁细胞产生胃酸。胃泌素通过称为胆囊收缩素(CCK) 或 CCK-B 受体 (CCK-BR) 的 G 蛋白偶联受体发挥其功能。胃泌素的释放受到食物的刺激,尤其是蛋白质饮食,并受到非常低的 pH 值的抑制。萎缩性胃炎、幽门螺杆菌感染和长期服用质子泵抑制剂感染可能导致胃泌素过度表达。胃腺癌显示高水平的胃泌素。 |